Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry
This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.
- Information on the top potential drug launches by pharma companies in 2019
- Knowledge about drug, mechanism of action, and briefing of clinical evidences
- Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
- Insights into regulatory approvals, market scope, and analysis of pipeline molecules
- Detailed profiles of the companies and competitors related to the industry
The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.